Patents by Inventor Hedva Gonen

Hedva Gonen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7507788
    Abstract: The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide fragments thereof comprise RHG and Trp-box amino acid consensus sequences. Stimulation/acceleration results in self-ubiquitination and auto-degradation of an IAP. For downmodulation/suppression of apoptosis, IAPi-derived proteins or peptide fragments thereof comprising either RHG or Trp-box amino acid consensus sequences, or both, failing to stimulate or suppressing self-ubiquitination and auto-degradation of an IAP, result in suppression of apoptosis.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: March 24, 2009
    Assignees: Rappaport Family Institute for Research in the Medical Sciences, Rockefeller Institute
    Inventors: Hermann Steller, Hyung Don Ryoo, Aaron Ciechanover, Hedva Gonen
  • Publication number: 20060058229
    Abstract: The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide fragments thereof comprise RHG and Trp-box amino acid consensus sequences. Stimulation/acceleration results in self-ubiquitination and auto-degradation of an IAP. For downmodulation/suppression of apoptosis, IAPi-derived proteins or peptide fragments thereof comprising either RHG or Trp-box amino acid consensus sequences, or both, failing to stimulate or suppressing self-ubiquitination and auto-degradation of an IAP, result in suppression of apoptosis.
    Type: Application
    Filed: May 8, 2003
    Publication date: March 16, 2006
    Inventors: Hermann Steller, Hyung Ryoo, Aaron Ciechanover, Hedva Gonen
  • Publication number: 20060003939
    Abstract: The present invention provides novel peptides, nucleic acids, compounds, compositions and methods for regulating apoptosis, and screening methods for identifying same. Regulation of apoptosis is mediated via IAPi-derived proteins, peptide fragments thereof, and nucleic acids encoding same, stimulating/accelerating or downmodulating/suppressing apoptosis. For stimulation/acceleration of apoptosis, the IAPi-derived proteins or peptide fragments thereof comprise RHG and Trp-box amino acid consensus sequences. Stimulation/acceleration results in self-ubiquitination and auto-degradation of an IAP. For downmodulation/suppression of apoptosis, IAPi-derived proteins or peptide fragments thereof comprising either RHG or Trp-box amino acid consensus sequences, or both, failing to stimulate or suppressing self-ubiquitination and auto-degradation of an IAP, result in suppression of apoptosis.
    Type: Application
    Filed: May 8, 2003
    Publication date: January 5, 2006
    Inventors: Hermann Steller, Hyung Ryoo, Aaron Ciechanover, Hedva Gonen
  • Patent number: 5384255
    Abstract: A method for isolating and purifying novel species of E2 ubiquitin-carrier protein, designated E2-F1, is disclosed. A method for preparing enzymatically active fragments of E2-F1 enzyme is also disclosed. The use of purified E2-F1 to produce antibodies is also disclosed. The use of such E2-F1-specific antibodies to detect the presence of E2-F1 in a biological sample, and to inhibit protein degradation are also disclosed. Recombinant DNA molecules which code for E2-F1, and recombinant hosts and vectors which contain E2-F1 coding sequences are also disclosed. The use of such recombinant hosts and vectors to produce E2-F1 protein is also disclosed. The use of purified E2-F1 to identify and to isolate E3 enzyme is also disclosed. Methods for screening substances for the ability to inhibit E2-F1 enzyme activity are also disclosed.
    Type: Grant
    Filed: June 21, 1993
    Date of Patent: January 24, 1995
    Assignee: Rappaport Family Institute for Research in the Medical Sciences
    Inventors: Aaron J. Ciechanover, Nava Blumenfeld, Hedva Gonen